Free Trial

Cresco Labs Inc. (OTCMKTS:CRLBF) Receives $3.00 Average Price Target from Analysts

Cresco Labs logo with Medical background

Shares of Cresco Labs Inc. (OTCMKTS:CRLBF - Get Free Report) have earned an average rating of "Buy" from the five analysts that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $3.00.

Separately, Cormark upgraded Cresco Labs from a "hold" rating to a "moderate buy" rating in a report on Monday, March 17th.

Read Our Latest Stock Report on Cresco Labs

Cresco Labs Stock Performance

Shares of CRLBF traded down $0.04 during mid-day trading on Thursday, reaching $0.63. The company had a trading volume of 363,896 shares, compared to its average volume of 677,722. The stock has a market capitalization of $309.39 million, a P/E ratio of -3.15 and a beta of 1.81. Cresco Labs has a 52-week low of $0.52 and a 52-week high of $2.60. The stock has a 50 day moving average of $0.74 and a two-hundred day moving average of $1.01. The company has a quick ratio of 1.39, a current ratio of 1.97 and a debt-to-equity ratio of 1.80.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last posted its quarterly earnings data on Friday, March 14th. The company reported ($0.01) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.01). Cresco Labs had a negative net margin of 9.15% and a negative return on equity of 16.52%. The company had revenue of $176.00 million during the quarter, compared to analysts' expectations of $172.10 million. On average, analysts expect that Cresco Labs will post -0.2 earnings per share for the current year.

About Cresco Labs

(Get Free Report

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.

Recommended Stories

Analyst Recommendations for Cresco Labs (OTCMKTS:CRLBF)

Should You Invest $1,000 in Cresco Labs Right Now?

Before you consider Cresco Labs, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cresco Labs wasn't on the list.

While Cresco Labs currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Buy Early: 3 Tech Trends With Millionaire-Making Potential
SMCI Stumbles on Earnings: Why Some Investors Still Want In
5 Stocks to BUY NOW in May 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines